Stock Pulse
Boston Scientific (BSX) is anticipated to announce Q1 2025 earnings on April 23rd, with projected EPS and revenue growth of 19.64% and 18.2% year-over-year, respectively [2], [3]. The stock price recently surged 6.8% on optimism regarding this upcoming release [3], but the unchanged consensus EPS estimate might limit further short-term gains [3]. While strong Q4 2024 results and positive long-term growth projections fueled by organic growth and strategic acquisitions signal continued positive momentum [7], [10], the stock experienced a previous dip due to broader market uncertainties [7]. Analysts hold mixed opinions, with a strong buy ABR but a Zacks Rank of #3 (Hold) [4]. Strong organic revenue growth and expanding free cash flow margins bolster the company's financial health [10].